Given that large-scale cancer analyses, such as the TCGA, have demonstrated a high rate of mutations in genes involved in SWI/SNFc (nearly 25% in more than 100,000 tumors), there is a strong rationale for accelerating research and finding therapeutic approaches that target SWI/SNF aberrations. This evidence concerns the gene SMARCA1 and cancer.